Ernexa Therapeutics Inc. — Director's Dealing 2021

Dec 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Brooklyn ImmunoTherapeutics, Inc. (BTX)
CIK: 0000748592
Period of Report: 2021-12-08

Reporting Person: LANGER DENNIS (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-08	Stock Option	$5.94	A	67000	Acquired	2031-12-07	Common Stock (67000)	Direct

Footnotes

F1: A total of 22,336 of the shares subject to the option vest and become exercisable as of 12:01 a.m. Eastern time on the date of the issuer's 2022 Annual Meeting of Stockholders and the remaining 44,664 shares vest and become exercisable in equal monthly installments over the following 24 months, subject to continued service through each vesting date.